The Effect of LY333531 on Protein in the Urine in Patients With Type 2 Diabetes

This study has been completed.
Sponsor:
Information provided by:
Eli Lilly and Company
ClinicalTrials.gov Identifier:
NCT00044148
First received: August 20, 2002
Last updated: July 18, 2006
Last verified: July 2006
  Purpose

The purpose of this study are to determine 1) Whether Ly333531 can reduce urinary albumin/creatinine excretion in patients with Type II diabetes and persistent albuminuria 2) Whether LY333531 reduces urinary TGF-B, 3) the safety of LY333531 and any side effects that may be associated with it.


Condition Intervention Phase
Diabetic Nephropathy
Drug: LY333531
Phase 2

Study Type: Interventional
Study Design: Primary Purpose: Treatment

Resource links provided by NLM:


Further study details as provided by Eli Lilly and Company:

  Eligibility

Ages Eligible for Study:   30 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Type 2 diabetes mellitus
  • Greater than or equal to 30 years of age
  • Albumin to Creatinine ratio (greater than 200 mg/g and less than 2000 mg/g) 4)Without language barrier.

Exclusion Criteria:

  • Serum Creatinine greater than 2.0 mg/dl males or greater than 1.7 mg/dl females
  • B/P greater than 150 systolic and greater than 90 diastolic
  • Hemoglobin Alc greater than 11%
  • Liver Function Tests 2 times upper limit of normal
  • Poor medical or psychiatric risk.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00044148

Locations
United States, California
La Jolla, California, United States
Walnut Creek, California, United States
United States, Florida
Jacksonville, Florida, United States
United States, Georgia
Atlanta, Georgia, United States
United States, Illinois
Chicago, Illinois, United States
United States, Kentucky
Lexington, Kentucky, United States
United States, Maryland
Baltimore, Maryland, United States
United States, Massachusetts
Waltham, Massachusetts, United States
United States, Minnesota
Minneapolis, Minnesota, United States
United States, Missouri
St Louis, Missouri, United States
United States, New York
New York, New York, United States
United States, North Carolina
Greenville, North Carolina, United States
United States, Texas
Dallas, Texas, United States
United States, Washington
Seattle, Washington, United States
Spokane, Washington, United States
Sponsors and Collaborators
Eli Lilly and Company
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00044148     History of Changes
Other Study ID Numbers: 6249, B7A-MC-MBDA
Study First Received: August 20, 2002
Last Updated: July 18, 2006
Health Authority: United States: Food and Drug Administration

Keywords provided by Eli Lilly and Company:
Persistent Albuminuria

Additional relevant MeSH terms:
Diabetic Nephropathies
Kidney Diseases
Urologic Diseases
Diabetes Complications
Diabetes Mellitus
Endocrine System Diseases
Ruboxistaurin
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions

ClinicalTrials.gov processed this record on April 17, 2014